Why the study?
Can fluorescence in situ hybridization detect mutant mRNA foci in improperly frozen or stored skeletal muscle biopsies from patients with myotonic dystrophy type 2?
Can fluorescence in situ hybridization detect mutant mRNA foci in improperly frozen or stored skeletal muscle biopsies from patients with myotonic dystrophy type 2?
Fluorescence in situ hybridization can reliably diagnose myotonic dystrophy type 2 even in skeletal muscle biopsies that have been improperly frozen or stored.
May allow DM2 diagnosis from archived or mishandled biopsies; leaves open prospective validation before clinical adoption.
Myotonic dystrophy type 2 (DM2) is a dominantly inherited disorder caused by a CCTG repeat expansion in intron 1 of ZNF9 gene. The size and the somatic instability of DM2 expansion complicate the molecular diagnosis of DM2. In situ hybridization represents a rapid and sensitive method to obtain a definitive diagnosis in few hours, since it allows the direct visualization of the mutant mRNA foci on skeletal muscle sections. This approach makes the muscle biopsy an important tool for definitive diagnosis of DM2. Consequently, a rapid freezing at ultra cold temperature and a good storage of muscle specimens are essential to avoid morphologic alterations and nucleic acids degradation. However incorrect freezing or thawing may accidentally occur. In this work we report that fluorescence in situ hybridization may be applied on improperly frozen or inappropriately stored muscle biopsies since foci of mutant mRNA are well preserved and can still be detected in muscle sections no more useful for histopathological evaluation.
No takes yet. Share an insight, caveat, or question.
Cardani et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: